With the number of US patent disputes between biologics innovators and makers of biosimilars increasing, we highlight five issues that IP professionals should have on their radar, including the impact of cases involving Amgen, Genentech, AbbVie and Boehringer Ingelheim
2 Mar
2020
Five developments to watch out for in biosimilar patent litigation
